Study to determine whether low-dose aspirin in healthy older adults prevents cognitive decline in those identified as having moderate to severe sleep apnoea: the SNORE-ASA substudy of the Aspirin in Reducing Events in the Elderly (ASPREE) study.

Phase 4

Active, not recruiting

• Conditions: Cognitive decline; Sleep Apnoea; Neurological - Dementias; Respiratory - Sleep apnoea

• Registration Number: ACTRN12612000891820
• Lead Sponsor: Monash University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-08-22
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: Active, not recruiting
• Sex: All
• Target Recruitment: 1500

Inclusion Criteria

Enrolling into the parent ASPREE study.
Aged 70 and over
Able and willing to provide informed consent

Exclusion Criteria

History of a diagnosed cardiovascular event, including AMI and stroke, atrial fibrillation, serious intercurrent illness likely to cause death within 5 years, cognitive impairment or dementia, disability, anaemia, a current or recurrent condition with a high risk of major bleeding, absolute contraindication or allergy to aspirin.

Also known history of sleep apnoea and/ or current use of continuous positive airways pressure (CPAP) at night

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Cognitive decline as measured by change in the modified mini mental state examination (3MS)[3 years]

Secondary Outcome Measures

Name	Time	Method
Change in brain MRI measures of white matter hyperintensity including volume[3 years];Change in Retinal Vascular Imaging (RVI) parameters[3 years];Cognitive decline as defined by a fall in summed average z-scores of >1 SD on any cognitive domain evaluated[3 years]